



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

ELI LILLY AND COMPANY

By Linda M. Durbin

Date January 18, 2005

**REISSUE PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants:	Harlan Edgar Shannon et al.	) Confirmation No.
		) 9165
Serial No.:	09/935,513	)
		) Group Art Unit:
Filed:	August 22, 2001	) 1617
		)
For:	Method for Treating Pain	) Examiner:
		) Theodore J. Criares
Docket No.:	X-10576A	)

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, Applicants submit a copy of each of the documents listed on the attached Form PTO-1449 (modified) for consideration by the Examiner.

Since this Statement is being filed after the period specified in §1.97(b), but before the mailing date of a final action or a notice of allowance, please charge the amount of \$180.00, the fee under 37 C.F.R. 1.17(p), and charge any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840.

01/25/2005 GWORD0F1 00000036 050840 09935513

01 FC:1806 180.00 DA

Applicants request consideration of this information.

Respectfully submitted,



Nelsen L. Lentz  
Attorney for Applicants  
Registration No. 38,537  
Phone: 317-276-1207

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

January 17, 2005



Sheet 1 of 1

FORM PTO 1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-10576A	Serial No 09/935/513
	Applicants Harlan Edgar Shannon et al.	
	Filing Date August 22, 2001	Group 1617

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	US			
	AB	US			
	AC	US			
	AD	US			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BA					
	BB					
	BC					

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
	CM	VAISHALI P. BAKSHI ET AL., Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine, Psychopharmacology 1995, 198-201, Vol. 122	
	CN	RAY W. FULLER ET AL., Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate, Research Communications in Chemical Pathology and Pharmacology, July 1992, 87-93, Vol. 77, No. 1	
	CO	NICHOLAS A. MOORE ET AL., The Behavioral Pharmacology of Olanzapine, a Novel "Atypical" Antipsychotic Agent, The Journal of Pharmacology and Experimental Therapeutics, 1992, 545-551, Vol. 262, No. 2	
	CP	FRANK P. BYMASTER ET AL., Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine, Neuropsychopharmacology, 1996, 87-96, Vol. 14, No. 2	
	CQ	SHELDON H. PRESKORN, MD ET AL., Polypharmacy: When Is It Rational?, Journal of Practical Psychiatry and Behavioral Health, July 1995, 92-98	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.